BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Ariad Pharmaceuticals, Inc. 

26 Landsdowne Street

Cambridge  Massachusetts  02139  U.S.A.
Phone: 617-494-0400 Fax: 617-494-8144


SEARCH JOBS

View Clinical Trials from BioPharm Insight

ARIAD Pharmaceuticals, Inc. is an emerging global oncology company focused on the discovery, development and commercialization of medicines to transform the lives of cancer patients. ARIAD’s approach to structure-based drug design has led to four internally discovered, molecularly targeted product candidates for drug-resistant and difficult-to-treat cancers, including certain forms of chronic myeloid leukemia, soft tissue and bone sarcomas and non-small cell lung cancer. Additional information about ARIAD can be found on the web at http://www.ariad.com.


Our focus at ARIAD is to discover and develop new drugs that will dramatically expand and improve current treatment options for patients with cancer. Our story starts with our vision, which reflects who we are, where we’re going and what we’re trying to do. Our mission and values keep us focused on the kind of company—and people—we want to be.


Our vision is to transform the lives of cancer patients with breakthrough medicines.
Our mission is to discover, develop and commercialize small-molecule drugs to treat cancer in patients with the greatest unmet medical need—aggressive cancers where current therapies are inadequate. We are committed to the highest standards of integrity and stewardship in service to patients, the medical community, employees and shareholders.



Values


• Mutual respect—we seek always to recognize and acknowledge every individual perspective.


• Integrity—we strive for honesty and transparency in our behavior, every day.


• Scientific excellence—we value innovation, creativity and individual initiative in our work.


• Teamwork—we believe in collaborative relationships and shared success.


• Clinical scholarship—our unique approach to clinical investigation aims at addressing the biological basis of disease.


• Execution—we are committed to acting decisively and delivering on our commitments in all we do.



Building a global commercial oncology company


ARIAD is building a global commercial oncology company. At the end of 2011, ARIAD raised a net of $243 million through a public offering of common stock that allows the company to prepare for commercial launches of ponatinib and retain its substantial potential commercial value.





 Key Statistics


Email:
Ownership: Public

Web Site: Ariad Pharmaceuticals, Inc.
Employees:
Symbol: ARIA
 









 Company News
Ariad Pharmaceuticals, Inc. (ARIA) To Webcast Conference Call On First Quarter 2014 Financial Results 4/16/2014 6:50:55 AM    More...
Ariad Pharmaceuticals, Inc. (ARIA) Announces Appointment Of Hugh Cole, Senior Pharmaceutical-Industry Executive, As Chief Business Officer 4/2/2014 7:38:45 AM    More...
Ariad Pharmaceuticals, Inc. (ARIA) Announces Initiation Of Pivotal Phase 2 ALTA Trial Of AP26113 In Patients With Non-Small Cell Lung Cancer 3/24/2014 7:36:33 AM    More...
Merck & Co., Inc. (MRK) Shoves Once-Promising $700 Million+ Drug Back To Ariad Pharmaceuticals, Inc. (ARIA) 2/27/2014 8:23:31 AM    More...
Ariad Pharmaceuticals, Inc. (ARIA) Reports 2013 Financial Results And Outlines Key Objectives For 2014 2/25/2014 7:41:57 AM    More...
Ariad Pharmaceuticals, Inc. (ARIA) Brings In Two Activist-Backed Directors Onto Board Of Directors 2/21/2014 7:11:36 AM    More...
Ariad Pharmaceuticals, Inc. (ARIA) To Present At The RBC Capital Markets Healthcare Conference 2/19/2014 7:27:12 AM    More...
Ariad Pharmaceuticals, Inc. (ARIA) To Host Conference Call And Webcast Discussion Of Fourth Quarter And Year-End 2013 Financial Results On February 25, 2014 2/10/2014 8:00:37 AM    More...
Investor Seeks Two Board Seats At Ariad Pharmaceuticals, Inc. (ARIA) 2/7/2014 6:59:51 AM    More...
Big Pharma Groups Including Eli Lilly and Company (LLY) Make "Friendly Approaches" For Ariad Pharmaceuticals, Inc. (ARIA) 1/23/2014 8:08:37 AM    More...
12345678910...